PROFILPELAJAR.COM

Centhaquine

Centhaquine
Clinical data
Trade namesLyfaquin
Other namesCenthaquin; PMZ-2010; Compound-7173
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
  • 2-[2-[4-(3-Methylphenyl)piperazin-1-yl]ethyl]quinoline
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC22H25N3
Molar mass331.463 g·mol−1
3D model (JSmol)
  • CC1=CC(=CC=C1)N2CCN(CC2)CCC3=NC4=CC=CC=C4C=C3
  • InChI=1S/C22H25N3/c1-18-5-4-7-21(17-18)25-15-13-24(14-16-25)12-11-20-10-9-19-6-2-3-8-22(19)23-20/h2-10,17H,11-16H2,1H3
  • Key:UJNWGFBJUHIJKK-UHFFFAOYSA-N

Centhaquine (brand name Lyfaquin) is a cardiovascular drug.[1] In India, it is approved for the treatment of hypovolemic shock.[2]

Centhaquine is a vasopressor that activates α2A- and α2B-adrenoreceptors.[3] It increases venous return and improves tissue perfusion. The drug has more recently been identified as a potent and selective serotonin 5-HT2C receptor agonist (EC50Tooltip half-maximal effective concentration = 35 nM).[4] It has no detectable activity at the serotonin 5-HT2B or 5-HT2C receptors.[4]

References

  1. ^ Gulati A, Jain D, Agrawal NR, Rahate P, Choudhuri R, Das S, et al. (June 2021). "Resuscitative Effect of Centhaquine (Lyfaquin®) in Hypovolemic Shock Patients: A Randomized, Multicentric, Controlled Trial". Advances in Therapy. 38 (6): 3223–3265. doi:10.1007/s12325-021-01760-4. PMC 8189997. PMID 33970455.
  2. ^ "Marketing authorization received for Lyfaquin (centhaquine) to treat patients with hypovolemic shock from Indian regulatory agency" (Press release). May 14, 2020. Archived from the original on August 9, 2022. Retrieved April 25, 2024.
  3. ^ Chalkias A, Pais G, Gulati A (March 2024). "Effect of Centhaquine on the Coagulation Cascade in Normal State and Uncontrolled Hemorrhage: A Multiphase Study Combining Ex Vivo and In Vivo Experiments in Different Species". International Journal of Molecular Sciences. 25 (6): 3494. doi:10.3390/ijms25063494. PMC 10970680. PMID 38542464.
  4. ^ a b Adhikari AS, Yadav A, Pandit S, Kumar S, Pandey VK, Maurya AK, et al. (26 November 2025). "Synthesis and Evaluation of Novel Aza-Aromatics as Dual 5-HT2A and 5-HT2C Receptor Agonists". ACS Medicinal Chemistry Letters acsmedchemlett.5c00505. doi:10.1021/acsmedchemlett.5c00505. ISSN 1948-5875. Retrieved 29 November 2025.
Stub icon

This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by adding missing information.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.